{"id":"NCT00883753","sponsor":"Hoffmann-La Roche","briefTitle":"An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy","officialTitle":"An Extension Phase of the Multi-National Open-Label Study (MA21573) to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2009-04-20","resultsPosted":"2014-08-06","lastUpdate":"2014-08-06"},"enrollment":934,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"tocilizumab","type":"EXPERIMENTAL"}],"summary":"This study was an extension to study MA21573 \\[NCT00750880\\], which was an open label single arm study to investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biological disease-modifying antirheumatic drugs (DMARDS), in patients with moderate to severe active rheumatoid arthritis. Patients who completed the 24 week core study, and had at least a moderate European League Against Rheumatism (EULAR) response, were eligible to enter this long-term extension study, and received tocilizumab 8 mg/kg intravenous (iv) every 4 weeks. The anticipated time on study treatment was 1-2 years, and the target sample size was \\> 500 individuals.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"108 Weeks","effectByArm":[{"arm":"Tocilizumab Monotherapy","deltaMin":65,"sd":null},{"arm":"Tocilizumab + 1 DMARD","deltaMin":68.6,"sd":null},{"arm":"Tocilizumab + > 1 DMARD","deltaMin":73.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":171,"countries":["Australia","Canada","Czechia","France","Greece","Hungary","Italy","Netherlands","Poland","Portugal","Romania","Saudi Arabia","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":60,"n":934},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}